Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia

• Status: Completed
• Trial end date: 2004-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Atorvastatin; Atorvastatin Calcium; Hypolipidemic Agents; Rosuvastatin Calcium; Simvastatin

Criteria

Inclusion Criteria:

• Discontinuation of all cholesterol lowing drugs, including dietary supplements.

• Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease.

Exclusion Criteria:

• The use of lipid lowering drugs or dietary supplements after Visit 1.

• Active arterial disease eg Unstable angina, or recent arterial surgery

• Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.

• Abnormal laboratory parameters as defined in the protocol.